Source/Disclosures
Source: Gudbrandsdottir S. Blood. 2013;121:1976-1981.
April 04, 2013
1 min read
Save

Rituximab improved dexamethasone response rates in immune thrombocytopenia

Source/Disclosures
Source: Gudbrandsdottir S. Blood. 2013;121:1976-1981.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The addition of rituximab to a dexamethasone regimen was associated with improved platelet response rates in a cohort of patients with immune thrombocytopenia, according to results of a randomized, open-label, phase 3 trial.

The study included 133 newly diagnosed adults. Eligibility criteria included platelet counts ≤25 × 109/L or ≤50 × 109/L with bleeding symptoms.

Researchers randomly assigned 71 patients to dexamethasone 40 mg/day for 4 days, and 62 patients were assigned this dexamethasone regimen plus rituximab (Rituxan, Genentech/Biogen Idec) 375 mg/m2 weekly for 4 weeks. The study protocol allowed patients a supplemental dexamethasone course every 1 to 4 weeks for up to six cycles.

Sustained response — defined as platelets ≥50 × 109/L — at 6 months follow-up served as the primary endpoint. The median follow-up duration was 922 days.

The endpoint was reached by 37% of patients in the dexamethasone-only group and 58% of patients in the combination group (P=.02).

Patients in the combination arm also demonstrated longer time to relapse (P=.03) and time to rescue treatment (P=.007).

Safety profiles indicated more grade 3 to 4 adverse events in the combination group (P=.04).